Weather , , 0°C

Irritable Bowel Syndrome (IBS) Market is Projected to Advance at Significant Growth Rate Owing to the Initiative by Key Companies in the Therapeutics Landscape

 Breaking News
  • No posts were found

Irritable Bowel Syndrome (IBS) Market is Projected to Advance at Significant Growth Rate Owing to the Initiative by Key Companies in the Therapeutics Landscape

June 17
22:46 2021
Irritable Bowel Syndrome (IBS) Market is Projected to Advance at Significant Growth Rate Owing to the Initiative by Key Companies in the Therapeutics Landscape

Delveinsight Business Research LLP

DelveInsight’s “Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Irritable Bowel Syndrome (IBS) Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Irritable Bowel Syndrome (IBS), also known as spastic colon, irritable colon, mucous colitis, and spastic colitis, is a long-term digestive system condition, which causes cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. The symptoms can vary in severity and duration from person to person. However, they last at least three months for at least three days per month. IBS can cause intestinal damage in some cases. The condition is separate from inflammatory bowel disease and isn’t related to other bowel conditions.

The cause is of IBS is unknown, but environmental factors such as changes of routine, emotional stress, infection, and diet can trigger an attack. Research has shown that the neurotransmitter serotonin may be important in IBS, altering the function of nerve cells in the bowel and causing changes in pain sensation and bowel function. In terms of prevalence, IBS is seen to be more common in females than in males.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market

The Irritable Bowel Syndrome (IBS) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Irritable Bowel Syndrome (IBS) market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Irritable Bowel Syndrome (IBS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Irritable Bowel Syndrome (IBS) Market Key Facts

  • As per the study conducted by the National Institute of Health in 2018, IBS is thought to affect 1 in 5 people at some point in their life, and it usually first develops when a person is between 20 and 30 years of age. Around twice as many women are affected as men.

  • As per the International Foundation for Gastrointestinal Disorders’ report of 2018: Irritable bowel syndrome (IBS) is the most common functional gastrointestinal (GI) disorder with worldwide prevalence rates ranging generally in the area of 10–15%. Among patients, about 40% of them have mild IBS, 35% suffer from moderate IBS, and 25% from severe IBS.

  • According to DelveInsight’s estimates, the total diagnosed prevalence of IBS in 7MM was found to be 101.5 Million in 2017.

Key Benefits of Irritable Bowel Syndrome (IBS) Market Report

  • Irritable Bowel Syndrome (IBS) market report provides an in-depth analysis of Irritable Bowel Syndrome (IBS) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Irritable Bowel Syndrome (IBS) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Irritable Bowel Syndrome (IBS) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Irritable Bowel Syndrome (IBS) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Irritable Bowel Syndrome (IBS) Market

The market size of Irritable Bowel Syndrome is expected to show a positive shift during the study period owing to the extensive research and development activities of pharmaceutical companies for developing the therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Irritable Bowel Syndrome (IBS) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

 The report gives a thorough detail of the Irritable Bowel Syndrome (IBS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

Irritable Bowel Syndrome (IBS) Epidemiology

The epidemiology section covers insights about the historical and current Irritable Bowel Syndrome (IBS) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Irritable Bowel Syndrome (IBS) Epidemiology Segmentation

  • Total Prevalence and Diagnosed Prevalence of Irritable Bowel Syndrome 

  • Diagnosed Prevalence of Irritable Bowel Syndrome by Types

  • Severity-specific diagnosed prevalence of Irritable Bowel Syndrome

  • Age-specific diagnosed prevalence of Irritable Bowel Syndrome

  • Gender-specific diagnosed prevalence of Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Irritable Bowel Syndrome (IBS) market or expected to get launched in the market during the study period. The analysis covers Irritable Bowel Syndrome (IBS) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Irritable Bowel Syndrome (IBS) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Irritable Bowel Syndrome (IBS) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Irritable Bowel Syndrome (IBS) emerging therapies.

Management of Irritable Bowel Syndrome consists primarily of providing psychological support and recommending dietary measures. The selection of pharmacologic treatment remains symptom-directed.

The dynamics of the Irritable Bowel Syndrome (IBS) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. Companies across the globe are diligently working towards the development of new treatment therapies for Irritable Bowel Syndrome.

Irritable Bowel Syndrome (IBS) Companies

  • Sofar S.p.A

  • Redhill Bio

  • Ardelyx Inc.

  • 4D pharma plc

  • Urovant Sciences GmbH

  • Cosmo Technologies Ltd.

And many others.

Irritable Bowel Syndrome (IBS) Therapies covered in the report include:

  • BEKINDA

  • Tenapanor

  • Vibegron

  • L. casei DG

  • Blautix

  • Rifamycin SV-MMX

And many more.

The launch of emerging therapies will significantly impact the Irritable Bowel Syndrome market during the forecast period.

Table of Content

1. Key Insights

2. Executive Summary 

3. Irritable Bowel Syndrome (IBS) Competitive Intelligence Analysis

4. Irritable Bowel Syndrome (IBS) Market Overview at a Glance

5. Irritable Bowel Syndrome (IBS) Disease Background and Overview

6. Irritable Bowel Syndrome (IBS) Patient Journey

7. Irritable Bowel Syndrome (IBS) Epidemiology and Patient Population

8. Irritable Bowel Syndrome (IBS) Treatment Algorithm, Current Treatment, and Medical Practices

9. Irritable Bowel Syndrome (IBS) Unmet Needs

10. Key Endpoints of Irritable Bowel Syndrome (IBS) Treatment

11. Irritable Bowel Syndrome (IBS) Marketed Products

12. Irritable Bowel Syndrome (IBS) Emerging Therapies

13. Irritable Bowel Syndrome (IBS) Seven Major Market Analysis

14. Attribute Analysis

15. Irritable Bowel Syndrome (IBS) Market Outlook (7 major markets)

16. Irritable Bowel Syndrome (IBS) Access and Reimbursement Overview

17. KOL Views on the Irritable Bowel Syndrome (IBS) Market.

18. Irritable Bowel Syndrome (IBS) Market Drivers

19. Irritable Bowel Syndrome (IBS) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market

Latest Reports By DelveInsight
Irritable Bowel Syndrome (IBS) Pipeline Insights
Irritable Bowel Syndrome (IBS) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Irritable Bowel Syndrome (IBS) Market.

Follicular Lymphoma Market
DelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Follicular Lymphoma market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

November 2021
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  

Categories